Summary
Maximizing the expression yields of recombinant whole antibodies and antibody fragments such as Fabs, single-chain Fvs and single-domain antibodies is highly desirable since it leads to lower production costs. Various eukaryotic and prokaryotic expression systems have been exploited to accommodate antibody expression but Escherichia coli systems have enjoyed popularity, in particular with respect to antibody fragments, because of their low cost and convenience. In many instances, product yields have been less than adequate and intrinsic and extrinsic variables have been investigated in an effort to improve yields. This review deals with various aspects of antibody expression in E. coli with a particular focus on single-domain antibodies.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Cortez-Retamozo V, Lauwereys M, Hassanzadeh GG, Gobert M, Conrath K, Muyldermans S, De Baetselier P, Revets H: Efficient tumor targeting by single-domain antibody fragments ofcamels. Int J Cancer 98: 456–462, 2002
Groner B, Hartmann C, Wels W: Therapeutic antibodies. Curr Mol Med 4: 539–547, 2004
Holt LJ, Herring C, Jespers LS, Woolven BP, Tomlinson IM: Domain antibodies: proteins fortherapy. Trends Biotechnol 21: 484–490, 2003
Hudson PJ, Souriau C: Recombinant antibodies for cancer diagnosis and therapy. Expert Opin Biol Ther 1: 845–855, 2001
Kipriyanov SM, Moldenhauer G, Little M: High level production of soluble single chainantibodies in small-scale Escherichia coli cultures. J Immunol Methods 200: 69–77, 1997
Maynard J, Georgiou G: Antibody engineering. Annu Rev Biomed Eng 2: 339–376, 2000
Revets H, De Baetselier P, Muyldermans S: Nanobodies as novel agents for cancer therapy.Expert Opin Biol Ther 5: 111–124, 2005
Souriau C, Hudson PJ: Recombinant antibodies for cancer diagnosis and therapy. Expert Opin Biol Ther 3: 305–318, 2003
Stockwin LH, Holmes S: Antibodies as therapeutic agents: vive la renaissance! Expert Opin Biol Ther 3: 1133–1152, 2003
Adair JR: Engineering antibodies for therapy. Immunol Rev 130: 5–40, 1992
Hoogenboom HR, Marks JD, Griffiths AD, Winter G: Building antibodies from their genes.Immunol Rev 130: 41–68, 1992
Kipriyanov SM, Le Gall F: Generation and production of engineered antibodies. Mol Biotechnol 26: 39–60, 2004
Plückthun A: Escherichia coli producing recombinant antibodies. Bioprocess Technol 19:233–252, 1994
Winter G: Synthetic human antibodies and a strategy for protein engineering. FEBS Lett430: 92–94, 1998
Humphreys DP, Sehdev M, Chapman AP, Ganesh R, Smith BJ, King LM, Glover DJ, Reeks DG, Stephens PE: High-level periplasmic expression in Escherichia coli using a eukaryoticsignal peptide: importance of codon usage at the 5' end of the coding sequence. Protein Expr Purif 20: 252–264, 2000
Jurado P, Ritz D, Beckwith J, de Lorenzo V, Fernandez LA: Production of functionalsingle-chain Fv antibodies in the cytoplasm of Escherichia coli. J Mol Biol 320: 1–10, 2002
Kipriyanov SM, Dubel S, Breitling F, Kontermann RE, Little M: Recombinant single-chain Fvfragments carrying C-terminal cysteine residues: production of bivalent and biotinylatedminiantibodies. Mol Immunol 31: 1047–1058, 1994
Kipriyanov SM, Moldenhauer G, Braunagel M, Reusch U, Cochlovius B, Le Gall F, Kouprianova OA, der Lieth CW, Little M: Effect of domain order on the activity of bacterially producedbispecific single-chain Fv antibodies. J Mol Biol 330: 99–111, 2003
Knappik A, Krebber C, Plückthun A: The effect of folding catalysts on the in vivo foldingprocess of different antibody fragments expressed in Escherichia coli. Biotechnology N Y11: 77–83, 1993
Luo D, Mah N, Krantz M, Wilde K, Wishart D, Zhang Y, Jacobs F, Martin L: Vl-linker-Vhorientation-dependent expression of single chain Fv-containing an engineereddisulfide-stabilized bond in the framework regions. J Biochem (Tokyo) 118: 825–831, 1995
Arndt KM, Muller KM, Plückthun A: Factors influencing the dimer to monomer transition ofan antibody single-chain Fv fragment. Biochemistry 37: 12918–12926, 1998
Atwell JL, Breheney KA, Lawrence LJ, McCoy AJ, Kortt AA, Hudson PJ: scFv multimers of theanti-neuraminidase antibody NC10: length of the linker between VH and VL domains dictatesprecisely the transition between diabodies and triabodies. Protein Eng 12: 597–604, 1999
Desplancq D, King DJ, Lawson AD, Mountain A: Multimerization behaviour of single chain Fvvariants for the tumour-binding antibody B72.3. Protein Eng 7: 1027–1033, 1994
Duenas M, Ayala M, Vazquez J, Ohlin M, Soderlind E, Borrebaeck CA, Gavilondo JV: A pointmutation in a murine immunoglobulin V-region strongly influences the antibody yield in Escherichia coli. Gene 158: 61–66, 1995
Forsberg G, Forsgren M, Jaki M, Norin M, Sterky C, Enhorning A, Larsson K, Ericsson M, Bjork P: Identification of framework residues in a secreted recombinant antibody fragmentthat control production level and localization in Escherichia coli. J Biol Chem 272:12430–12436, 1997
Jung S, Honegger A, Plückthun A: Selection for improved protein stability by phagedisplay. J Mol Biol 294: 163–180, 1999
Nieba L, Honegger A, Krebber C, Plückthun A: Disrupting the hydrophobic patches at theantibody variable/constant domain interface: Improved in vivo folding and physicalcharacterization of an engineered scFv fragment. Protein Eng 10: 435–444, 1997
Woo JH, Liu YY, Mathias A, Stavrou S, Wang Z, Thompson J, Neville DM, Jr.: Geneoptimization is necessary to express a bivalent anti-human anti-T cell immunotoxin in Pichia pastoris. Protein Expr Purif 25: 270–282, 2002
Better M, Chang CP, Robinson RR, Horwitz AH: Escherichia coli secretion of an activechimeric antibody fragment. Science 240: 1041–1043, 1988
Skerra A, Plückthun A: Assembly of a functional immunoglobulin Fv fragment in Escherichiacoli. Science 240: 1038–1041, 1988
Pollock DP, Kutzko JP, Birck-Wilson E, Williams JL, Echelard Y, Meade HM: Transgenic milkas a method for the production of recombinant antibodies. J Immunol Methods 231: 147–157, 1999
Young MW, Meade H, Curling JM, Ziomek CA, Harvey M: Production of recombinant antibodiesin the milk of transgenic animals. Res Immunol 149: 609–610, 1998
Biocca S, Ruberti F, Tafani M, Pierandrei-Amaldi P, Cattaneo A: Redox state of singlechain Fv fragments targeted to the endoplasmic reticulum, cytosol and mitochondria.Biotechnology (NY) 13: 1110–1115, 1995
Schouten A, Roosien J, van Engelen FA, de Jong GA, Borst-Vrenssen AW, Zilverentant JF, Bosch D, Stiekema WJ, Gommers FJ, Schots A, Bakker J: The C-terminal KDEL sequenceincreases the expression level of a single-chain antibody designed to be targeted to boththe cytosol and the secretory pathway in transgenic tobacco. Plant Mol Biol 30: 781–793, 1996
Tewari D, Goldstein SL, Notkins AL, Zhou P: cDNA encoding a single-chain antibody to HIVp17 with cytoplasmic or nuclear retention signals inhibits HIV-1 replication. J Immunol161: 2642–2647, 1998
Boder ET, Midelfort KS, Wittrup KD: Directed evolution of antibody fragments withmonovalent femtomolar antigen-binding affinity. Proc Natl Acad Sci USA 97: 10701–10705, 2000
Carter P, Kelley RF, Rodrigues ML, Snedecor B, Covarrubias M, Velligan MD, Wong WL, Rowland AM, Kotts CE, Carver ME: High level Escherichia coli expression and productionof a bivalent humanized antibody fragment. Biotechnology (NY) 10: 163–167, 1992
Griffiths AD, Williams SC, Hartley O, Tomlinson IM, Waterhouse P, Crosby WL, Kontermann RE, Jones PT, Low NM, Allison TJ, et al: Isolation of high affinity human antibodiesdirectly from large synthetic repertoires. EMBO J 13: 3245–3260, 1994
Humphreys DP, Glover DJ: Therapeutic antibody production technologies: Molecules, applications, expression and purification. Curr Opin Drug Discov Devel 4: 172–185, 2001
Joosten V, Lokman C, van den Hondel CA, Punt PJ: The production of antibody fragments andantibody fusion proteins by yeasts and filamentous fungi. Microb Cell Fact 2: 1, 2003
Miller KD, Weaver-Feldhaus J, Gray SA, Siegel RW, Feldhaus MJ: Production, purification, and characterization of human scFv antibodies expressed in Saccharomyces cerevisiae, Pichia pastoris, and Escherichia coli. Protein Expr Purif 2005
Worn A, Plückthun A: Different equilibrium stability behavior of ScFv fragments:Identification, classification, and improvement by protein engineering. Biochemistry 38:8739–8750, 1999
Worn A, Plückthun A: Stability engineering of antibody single-chain Fv fragments. J Mol Biol 305: 989–1010, 2001
Oelschlaeger P, Lange S, Schmitt J, Siemann M, Reuss M, Schmid RD: Identification offactors impeding the production of a single-chain antibody fragment in Escherichia coli bycomparing in vivo and in vitro expression. Appl Microbiol Biotechnol 61: 123–132, 2003
Wulfing C, Plückthun A: Protein folding in the periplasm of Escherichia coli. Mol Microbiol 12: 685–692, 1994
Dumoulin M, Conrath K, Van Meirhaeghe A, Meersman F, Heremans K, Frenken LG, Muyldermans S, Wyns L, Matagne A: Single-domain antibody fragments with high conformational stability.Protein Sci 11: 500–515, 2002
Stanfield RL, Dooley H, Flajnik MF, Wilson IA: Crystal structure of a shark single-domainantibody V region in complex with lysozyme. Science 305: 1770–1773, 2004
Greenberg AS, Avila D, Hughes M, Hughes A, McKinney EC, Flajnik MF: A new antigen receptorgene family that undergoes rearrangement and extensive somatic diversification in sharks.Nature 374: 168–173, 1995
Hamers-Casterman C, Atarhouch T, Muyldermans S, Robinson G, Hamers C, Songa EB, Bendahman N, Hamers R: Naturally occurring antibodies devoid of light chains. Nature 363: 446–448, 1993
Muyldermans S, Atarhouch T, Saldanha J, Barbosa JA, Hamers R: Sequence and structure of VHdomain from naturally occurring camel heavy chain immunoglobulins lacking light chains.Protein Eng 7: 1129–1135, 1994
Vu KB, Arbabi-Ghahroudi M, Wyns L, Muyldermans S: Comparison of llama VH sequences fromconventional and heavy chain antibodies. Mol Immunol 34: 1121–1131, 1997
Arbabi-Ghahroudi M, Desmyter A, Wyns L, Hamers R, Muyldermans S: Selection andidentification of single domain antibody fragments from camel heavy-chain antibodies. FEBSLett 414: 521–526, 1997
Desmyter A, Transue TR, Arbabi-Ghahroudi M, Thi MH, Poortmans F, Hamers R, Muyldermans S, Wyns L: Crystal structure of a camel single-domain VH antibody fragment in complex withlysozyme. Nat Struct Biol 3: 803–811, 1996
Roux KH, Greenberg AS, Greene L, Strelets L, Avila D, McKinney EC, Flajnik MF: Structuralanalysis of the nurse shark (new) antigen receptor (NAR): molecular convergence of NAR andunusual mammalian immunoglobulins. Proc Natl Acad Sci USA 95: 11804–11809, 1998
Bond CJ, Marsters JC, Sidhu SS: Contributions of CDR3 to VHH domain stability and thedesign of monobody scaffolds for naive antibody libraries. J Mol Biol 332: 643–655, 2003
Dolk E, van der Vaart M, Lutje HD, Vriend G, de Haard H, Spinelli S, Cambillau C, Frenken L, Verrips T: Isolation of llama antibody fragments for prevention of dandruff by phagedisplay in shampoo. Appl Environ Microbiol 71: 442–450, 2005
Ewert S, Cambillau C, Conrath K, Plückthun A: Biophysical properties of camelid VHHdomains compared to those of human VH3 domains. Biochemistry 41: 3628–3636, 2002
Jespers L, Schon O, James LC, Veprintsev D, Winter G: Crystal Structure of HEL4, a Soluble, Refoldable Human VH Single Domain with a Germ-line Scaffold. J Mol Biol 337:893–903, 2004
Jespers L, Schon O, Famm K, Winter G: Aggregation-resistant domain antibodies selected onphage by heat denaturation. Nat Biotechnol 22: 1161–1165, 2004
Jobling SA, Jarman C, Teh MM, Holmberg N, Blake C, Verhoeyen ME: Immunomodulation ofenzyme function in plants by single-domain antibody fragments. Nat Biotechnol 21: 77–80, 2003
Muruganandam A, Tanha J, Narang S, Stanimirovic D: Selection of phage-displayed llamasingle-domain antibodies that transmigrate across human blood-brain barrier endothelium.FASEB J 16: 240–242, 2002
Kujau MJ, Hoischen C, Riesenberg D, Gumpert J: Expression and secretion of functionalminiantibodies McPC603scFv Dhlx in cell-wall-less L-form strains of Proteus mirabilis and Escherichia coli: A comparison of the synthesis capacities of L-form strains with an E.coli producer strain. Appl Microbiol Biotechnol 49: 51–58, 1998
Pschorr J, Bieseler B, Fritz HJ: Production of the immunoglobulin variable domain REIv viaa fusion protein synthesized and secreted by Staphylococcus carnosus. Biol Chem Hoppe Seyler 375: 271–280, 1994
Rippmann JF, Klein M, Hoischen C, Brocks B, Rettig WJ, Gumpert J, Pfizenmaier K, Mattes R, Moosmayer D: Procaryotic expression of single-chain variable-fragment (scFv) antibodies:Secretion in L-form cells of Proteus mirabilis leads to active product and overcomes thelimitations of periplasmic expression in Escherichia coli. Appl Environ Microbiol 64:4862–4869, 1998
Ueda Y, Tsumoto K, Watanabe K, Kumagai I: Synthesis and expression of a DNA encoding the Fv domain of an anti-lysozyme monoclonal antibody, Hy HEL10, in Streptomyces lividans. Gene129: 129–134, 1993
Wu SC, Yeung JC, Duan Y, Ye R, Szarka SJ, Habibi HR, Wong SL: Functional production andcharacterization of a fibrin-specific single-chain antibody fragment from Bacillussubtilis: Effects of molecular chaperones and a wall-bound protease on antibody fragmentproduction. Appl Environ Microbiol 68: 3261–3269, 2002
Wu XC, Ng SC, Near RI, Wong SL: Efficient production of a functional single-chainantidigoxin antibody via an engineered Bacillus subtilis expression-secretion system.Biotechnology (N Y) 11: 71–76, 1993
Fischer R, Drossard J, Emans N, Commandeur U, Hellwig S: Towards molecular farming in thefuture: pichia pastoris-based production of single-chain antibody fragments. Biotechnol Appl Biochem 30 (Pt 2): 117–120, 1999
Franklin SE, Mayfield SP: Recent developments in the production of human therapeuticproteins in eukaryotic algae. Expert Opin Biol Ther 5: 225–235, 2005
Reavy B, Ziegler A, Diplexcito J, Macintosh SM, Torrance L, Mayo M: Expression offunctional recombinant antibody molecules in insect cell expression systems. Protein Expr Purif 18: 221–228, 2000
Nolke G, Fischer R, Schillberg S: Production of therapeutic antibodies in plants. Expert Opin Biol Ther 3: 1153–1162, 2003
Andersen DC, Krummen L: Recombinant protein expression for therapeutic applications. Curr Opin Biotechnol 13: 117–123, 2002
Meissner P, Pick H, Kulangara A, Chatellard P, Friedrich K, Wurm FM: Transient geneexpression: recombinant protein production with suspension-adapted HEK293-EBNA cells.Biotechnol Bioeng 75: 197–203, 2001
Trill JJ, Shatzman AR, Ganguly S: Production of monoclonal antibodies in COS and CHOcells. Curr Opin Biotechnol 6: 553–560, 1995
Simmons LC, Reilly D, Klimowski L, Raju TS, Meng G, Sims P, Hong K, Shields RL, Damico LA, Rancatore P, Yansura DG: Expression of full-length immunoglobulins in Escherichia coli:rapid and efficient production of aglycosylated antibodies. J Immunol Methods 263:133–147, 2002
Boss MA, Kenten JH, Wood CR, Emtage JS: Assembly of functional antibodies fromimmunoglobulin heavy and light chains synthesised in E. coli. Nucleic Acids Res 12:3791–3806, 1984
Guo JQ, You SY, Li L, Zhang YZ, Huang JN, Zhang CY: Construction and high-level expressionof a single-chain Fv antibody fragment specific for acidic isoferritin in Escherichiacoli. J Biotechnol 102: 177–189, 2003
Lee MH, Park TI, Park YB, Kwak JW: Bacterial expression and in vitro refolding of asingle-chain fv antibody specific for human plasma apolipoprotein B-100. Protein Expr Purif 25: 166–173, 2002
Martineau P, Jones P, Winter G: Expression of an antibody fragment at high levels in thebacterial cytoplasm. J Mol Biol 280: 117–127, 1998
Riesenberg D: High-cell-density cultivation of Escherichia coli. Curr Opin Biotechnol 2:380–384, 1991
Proba K, Honegger A, Plückthun A: A natural antibody missing a cysteine in VH:consequences for thermodynamic stability and folding. J Mol Biol 265: 161–172, 1997
Proba K, Worn A, Honegger A, Plückthun A: Antibody scFv fragments without disulfide bondsmade by molecular evolution. J Mol Biol 275: 245–253, 1998
Ewert S, Honegger A, Plückthun A: Stability improvement of antibodies for extracellularand intracellular applications: CDR grafting to stable frameworks and structure-basedframework engineering. Methods 34: 184–199, 2004
Worn A, Plückthun A: An intrinsically stable antibody scFv fragment can tolerate the lossof both disulfide bonds and fold correctly. FEBS Lett 427: 357–361, 1998
Buchner J, Brinkmann U, Pastan I: Renaturation of a single-chain immunotoxin facilitatedby chaperones and protein disulfide isomerase. Biotechnology (N Y) 10: 682–685, 1992
Fernandez LA: Prokaryotic expression of antibodies and affibodies. Curr Opin Biotechnol15: 364–373, 2004
Huston JS, Mudgett-Hunter M, Tai M-S, McCartney J, Warren F, Haber E, Oppermann H: Proteinengineering of single-chain Fv analogs and fusion proteins. Methods Enzymol 203: 46–88, 1991
Pugsley AP: The complete general secretory pathway in gram-negative bacteria. Microbiol Rev 57: 50–108, 1993
Bothmann H, Plückthun A: Selection for a periplasmic factor improving phage display andfunctional periplasmic expression. Nat Biotechnol 16: 376–380, 1998
Bothmann H, Plückthun A: The periplasmic Escherichia coli peptidylprolylcis, trans-isomerase Fkp A. I. Increased functional expression of antibody fragments withand without cis-prolines. J Biol Chem 275: 17100–17105, 2000
Chen C, Snedecor B, Nishihara JC, Joly JC, McFarland N, Andersen DC, Battersby JE, Champion KM: High-level accumulation of a recombinant antibody fragment in the periplasmof Escherichia coli requires a triple-mutant (deg P prc spr) host strain. Biotechnol Bioeng85: 463–474, 2004
Tanha J, Dubuc G, Hirama T, Narang SA, MacKenzie CR: Selection by phage display of llamaconventional VH fragments with heavy chain antibody VHH properties. J Immunol Methods263: 97–109, 2002
Fernandez LA, Sola I, Enjuanes L, de Lorenzo V: Specific secretion of active single-chain Fv antibodies into the supernatants of Escherichia coli cultures by use of the hemolysinsystem. Appl Environ Microbiol 66: 5024–5029, 2000
Fraile S, Munoz A, de Lorenzo V, Fernandez LA: Secretion of proteins with dimerizationcapacity by the haemolysin type I transport system of Escherichia coli. Mol Microbiol 53:1109–1121, 2004
Gentschev I, Dietrich G, Goebel W: The E. coli alpha-hemolysin secretion system and itsuse in vaccine development. Trends Microbiol 10: 39–45, 2002
Daugherty PS, Olsen MJ, Iverson BL, Georgiou G: Development of an optimized expressionsystem for the screening of antibody libraries displayed on the Escherichia coli surface.Protein Eng 12: 613–621, 1999
Skerra A: Use of the tetracycline promoter for the tightly regulated production of amurine antibody fragment in Escherichia coli. Gene 151: 131–135, 1994
Humphreys DP, Carrington B, Bowering LC, Ganesh R, Sehdev M, Smith BJ, King LM, Reeks DG, Lawson A, Popplewell AG: A plasmid system for optimization of Fab' production in Escherichia coli: Importance of balance of heavy chain and light chain synthesis. Protein Expr Purif 26: 309–320, 2002
Le Gall F, Reusch U, Moldenhauer G, Little M, Kipriyanov SM: Immunosuppressive propertiesof anti-CD3 single-chain Fv and diabody. J Immunol Methods 285: 111–127, 2004
Trinh R, Gurbaxani B, Morrison SL, Seyfzadeh M: Optimization of codon pair use within the(GGGGS)3 linker sequence results in enhanced protein expression. Mol Immunol 40: 717–722, 2004
Skerra A, Plückthun A: Secretion and in vivo folding of the Fab fragment of the antibody McPC603 in Escherichia coli: Influence of disulphides and cis-prolines. Protein Eng 4:971–979, 1991
Chames P, Fieschi J, Baty D: Production of a soluble and active MBP-scFv fusion: Favorableeffect of the leaky tol R strain. FEBS Lett 405: 224–228, 1997
Corisdeo S, Wang B: Functional expression and display of an antibody Fab fragment in Escherichia coli: Study of vector designs and culture conditions. Protein Expr Purif 34:270–279, 2004
Duenas M, Vazquez J, Ayala M, Soderlind E, Ohlin M, Perez L, Borrebaeck CA, Gavilondo JV:Intra- and extracellular expression of an scFv antibody fragment in E. coli: Effect ofbacterial strains and pathway engineering using Gro ES/L chaperonins. Bio Techniques 16:476–3, 1994
Freyre FM, Vazquez JE, Ayala M, Canaan-Haden L, Bell H, Rodriguez I, Gonzalez A, Cintado A, Gavilondo JV: Very high expression of an anti-carcinoembryonic antigen single chain Fvantibody fragment in the yeast Pichia pastoris. J Biotechnol 76: 157–163, 2000
Zhu Z, Zapata G, Shalaby R, Snedecor B, Chen H, Carter P: High level secretion of ahumanized bispecific diabody from Escherichia coli. Biotechnology (N Y) 14: 192–196, 1996
Gutierrez G, Marquez L, Marin A: Preference for guanosine at first codon position inhighly expressed Escherichia coli genes. A relationship with translational efficiency.Nucleic Acids Res 24: 2525–2527, 1996
Nakamura Y, Wada K, Wada Y, Doi H, Kanaya S, Gojobori T, Ikemura T: Codon usage tabulatedfrom the international DNA sequence databases. Nucleic Acids Res 24: 214–215, 1996
Robinson M, Lilley R, Little S, Emtage JS, Yarranton G, Stephens P, Millican A, Eaton M, Humphreys G: Codon usage can affect efficiency of translation of genes in Escherichiacoli. Nucleic Acids Res 12: 6663–6671, 1984
Wada K, Wada Y, Ishibashi F, Gojobori T, Ikemura T: Codon usage tabulated from the Gen Bankgenetic sequence data. Nucleic Acids Res 20 Suppl: 2111–2118, 1992
Gutman GA, Hatfield GW: Nonrandom utilization of codon pairs in Escherichia coli. ProcNatl Acad Sci USA 86: 3699–3703, 1989
Irwin B, Heck JD, Hatfield GW: Codon pair utilization biases influence translationalelongation step times. J Biol Chem 270: 22801–22806, 1995
Kotula L, Curtis PJ: Evaluation of foreign gene codon optimization in yeast: Expression ofa mouse IG kappa chain. Biotechnology (NY) 9: 1386–1389, 1991
Baca AM, Hol WG: Overcoming codon bias: a method for high-level overexpression of Plasmodium and other AT-rich parasite genes in Escherichia coli. Int J Parasitol 30:113–118, 2000
Zahn K: Overexpression of an m RNA dependent on rare codons inhibits protein synthesis andcell growth. J Bacteriol 178: 2926–2933, 1996
Zhou Z, Schnake P, Xiao L, Lal AA: Enhanced expression of a recombinant malaria candidatevaccine in Escherichia coli by codon optimization. Protein Expr Purif 34: 87–94, 2004
Stemmer WP, Morris SK, Kautzer CR, Wilson BS: Increased antibody expression from Escherichia coli through wobble-base library mutagenesis by enzymatic inverse PCR. Gene123: 1–7, 1993
Forrer P, Jung S, Plückthun A: Beyond binding: using phage display to select forstructure, folding and enzymatic activity in proteins. Curr Opin Struct Biol 9: 514–520, 1999
Deng SJ, MacKenzie CR, Sadowska J, Michniewicz J, Young NM, Bundle DR, Narang SA:Selection of antibody single-chain variable fragments with improved carbohydrate bindingby phage display. J Biol Chem 269: 9533–9538, 1994
Jackson JR, Sathe G, Rosenberg M, Sweet R: In vitro antibody maturation. Improvement of ahigh affinity, neutralizing antibody against IL-1 beta. J Immunol 154: 3310–3319, 1995
Jermutus L, Honegger A, Schwesinger F, Hanes J, Plückthun A: Tailoring in vitro evolutionfor protein affinity or stability. Proc Natl Acad Sci U S A 98: 75–80, 2001
Shusta EV, Holler PD, Kieke MC, Kranz DM, Wittrup KD: Directed evolution of a stablescaffold for T-cell receptor engineering. Nat Biotechnol 18: 754–759, 2000
Graff CP, Chester K, Begent R, Wittrup KD: Directed evolution of an anti-carcinoembryonicantigen scFv with a 4-day monovalent dissociation half-time at 37 degrees C. Protein Eng Des Sel 17: 293–304, 2004
Jung S, Plückthun A: Improving in vivo folding and stability of a single-chain Fv antibodyfragment by loop grafting. Protein Eng 10: 959–966, 1997
Kipriyanov SM, Moldenhauer G, Martin AC, Kupriyanova OA, Little M: Two amino acidmutations in an anti-human CD3 single chain Fv antibody fragment that affect the yield onbacterial secretion but not the affinity. Protein Eng 10: 445–453, 1997
Davies J, Riechmann L: ‘Camelising’ human antibody fragments: NMR studies on VH domains.FEBS Lett 339: 285–290, 1994
Davies J, Riechmann L: Antibody VH domains as small recognition units. Biotechnology NY13: 475–479, 1995
Tanha J, Xu P, Chen ZG, Ni F, Kaplan H, Narang SA, MacKenzie CR: Optimal design featuresof camelized human single-domain antibody libraries. J Biol Chem 276: 24774–24780, 2001
Ohage E, Steipe B: Intrabody construction and expression. I. The critical role of VLdomain stability. J Mol Biol 291: 1119–1128, 1999
Bardwell JC: Building bridges: Disulphide bond formation in the cell. Mol Microbiol 14:199–205, 1994
Knarr G, Gething MJ, Modrow S, Buchner J: Bi P binding sequences in antibodies. J Biol Chem270: 27589–27594, 1995
Rietsch A, Beckwith J: The genetics of disulfide bond metabolism. Annu Rev Genet 32:163–184, 1998
Hanes J, Jermutus L, Plückthun A: Selecting and evolving functional proteins in vitro byribosome display. Methods Enzymol 328: 404–430, 2000
Lilie H, Lang K, Rudolph R, Buchner J: Prolyl isomerases catalyze antibody folding invitro. Protein Sci 2: 1490–1496, 1993
Ryabova LA, Desplancq D, Spirin AS, Plückthun A: Functional antibody production usingcell-free translation: Effects of protein disulfide isomerase and chaperones. Nat Biotechnol 15: 79–84, 1997
Ying BW, Taguchi H, Ueda H, Ueda T: Chaperone-assisted folding of a single-chain antibodyin a reconstituted translation system. Biochem Biophys Res Commun 320: 1359–1364, 2004
Allen SP, Polazzi JO, Gierse JK, Easton AM: Two novel heat shock genes encoding proteinsproduced in response to heterologous protein expression in Escherichia coli. J Bacteriol174: 6938–6947, 1992
Schwarz E, Lilie H, Rudolph R: The effect of molecular chaperones on in vivo and in vitrofolding processes. Biol Chem 377: 411–416, 1996
Amrein KE, Takacs B, Stieger M, Molnos J, Flint NA, Burn P: Purification andcharacterization of recombinant human p50csk protein-tyrosine kinase from an Escherichiacoli expression system overproducing the bacterial chaperones Gro ES and Gro EL. Proc Natl Acad Sci USA 92: 1048–1052, 1995
Goloubinoff P, Gatenby AA, Lorimer GH: Gro E heat-shock proteins promote assembly offoreign prokaryotic ribulose bisphosphate carboxylase oligomers in Escherichia coli.Nature 337: 44–47, 1989
Gragerov A, Nudler E, Komissarova N, Gaitanaris GA, Gottesman ME, Nikiforov V: Cooperationof Gro EL/Gro ES and Dna K/Dna J heat shock proteins in preventing protein misfolding in Escherichia coli. Proc Natl Acad Sci USA 89: 10341–10344, 1992
Lee SC, Olins PO: Effect of overproduction of heat shock chaperones Gro ESL and Dna K onhuman procollagenase production in Escherichia coli. J Biol Chem 267: 2849–2852, 1992
Ideno A, Furutani M, Iba Y, Kurosawa Y, Maruyama T: FK506 binding protein from thehyperthermophilic archaeon Pyrococcus horikoshii suppresses the aggregation of proteins in Escherichia coli. Appl Environ Microbiol 68: 464–469, 2002
Ramm K, Plückthun A: The periplasmic Escherichia coli peptidylprolyl cis, trans-isomerase Fkp A. II. Isomerase-independent chaperone activity in vitro. J Biol Chem 275:17106–17113, 2000
Hayhurst A, Harris WJ: Escherichia coli skp chaperone coexpression improves solubility andphage display of single-chain antibody fragments. Protein Expr Purif 15: 336–343, 1999
Levy R, Weiss R, Chen G, Iverson BL, Georgiou G: Production of correctly folded Fabantibody fragment in the cytoplasm of Escherichia coli trx B gor mutants via thecoexpression of molecular chaperones. Protein Expr Purif 23: 338–347, 2001
Nishihara K, Kanemori M, Yanagi H, Yura T: Overexpression of trigger factor preventsaggregation of recombinant proteins in Escherichia coli. Appl Environ Microbiol 66:884–889, 2000
Langer T, Lu C, Echols H, Flanagan J, Hayer MK, Hartl FU: Successive action of Dna K, Dna Jand Gro EL along the pathway of chaperone-mediated protein folding. Nature 356: 683–689, 1992
Blum P, Ory J, Bauernfeind J, Krska J: Physiological consequences of Dna K and Dna Joverproduction in Escherichia coli. J Bacteriol 174: 7436–7444, 1992
O Kandror, M Sherman, Goldberg A: Rapid degradation of an abnormal protein in Escherichiacoli proceeds through repeated cycles of association with Gro EL. J Biol Chem 274:37743–37749, 1999
Georgiou G, Valax P: Expression of correctly folded proteins in Escherichia coli. Curr Opin Biotechnol 7: 190–197, 1996
Mertens N, Devos F, Leoen J, Van Deynse E, Willems A, Schoonooghe S, Burvenich I, De Koker S, Vlieghe D, Grooten J, Kelly A, Van de Wiele C: New strategies in polypeptide andantibody synthesis: an overview. Cancer Biother Radiopharm 19: 99–109, 2004
Lavallie ER, McCoy JM: Gene fusion expression systems in Escherichia coli. Curr Opin Biotechnol 6: 501–506, 1995
Bach H, Mazor Y, Shaky S, Shoham-Lev A, Berdichevsky Y, Gutnick DL, Benhar I: Escherichiacoli maltose-binding protein as a molecular chaperone for recombinant intracellularcytoplasmic single-chain antibodies. J Mol Biol 312: 79–93, 2001
Bregegere F, Schwartz J, Bedouelle H: Bifunctional hybrids between the variable domains ofan immunoglobulin and the maltose-binding protein of Escherichia coli: production, purification and antigen binding. Protein Eng 7: 271–280, 1994
di Guan C, Li P, Riggs PD, Inouye H: Vectors that facilitate the expression andpurification of foreign peptides in Escherichia coli by fusion to maltose-binding protein.Gene 67: 21–30, 1988
Zheng L, Baumann U, Reymond JL: Production of a functional catalytic antibody ScFv-Nus Afusion protein in bacterial cytoplasm. J Biochem (Tokyo) 133: 577–581, 2003
Wilkinson DL, Harrison RG: Predicting the solubility of recombinant proteins in Escherichia coli. Biotechnology (N Y) 9: 443–448, 1991
Hayhurst A: Improved expression characteristics of single-chain Fv fragments when fuseddownstream of the Escherichia coli maltose-binding protein or upstream of a singleimmunoglobulin-constant domain. Protein Expr Purif 18: 1–10, 2000
Cohen PA, Mani JC, Lane DP: Characterization of a new intrabody directed against the N-terminal region of human p53. Oncogene 17: 2445–2456, 1998
Ideno A, Furutani M, Iwabuchi T, Iida T, Iba Y, Kurosawa Y, Sakuraba H, Ohshima T, Kawarabayashi Y, Maruyama T: Expression of foreign proteins in Escherichia coli by fusingwith an archaeal FK506 binding protein. Appl Microbiol Biotechnol 64: 99–105, 2004
Kapust RB, Waugh DS: Escherichia coli maltose-binding protein is uncommonly effective atpromoting the solubility of polypeptides to which it is fused. Protein Sci 8: 1668–1674, 1999
Ward ES, Gussow D, Griffiths AD, Jones PT, Winter G: Binding activities of a repertoire ofsingle immunoglobulin variable domains secreted from Escherichia coli. Nature 341:544–546, 1989
Reiter Y, Schuck P, Boyd LF, Plaksin D: An antibody single-domain phage display library ofa native heavy chain variable region: isolation of functional single-domain VH moleculeswith a unique interface. J Mol Biol 290: 685–698, 1999
Davies J, Riechmann L: Single antibody domains as small recognition units: Design and invitro antigen selection of camelized, human VH domains with improved protein stability.Protein Eng 9: 531–537, 1996
van den Beucken T, van Neer N, Sablon E, Desmet J, Celis L, Hoogenboom HR, Hufton SE:Building novel binding ligands to B7.1 and B7.2 based on human antibody single variablelight chain domains. J Mol Biol 310: 591–601, 2001
Muyldermans S, Cambillau C, Wyns L: Recognition of antigens by single-domain antibodyfragments: The superfluous luxury of paired domains. Trends Biochem Sci 26: 230–235, 2001
Padlan EA: Anatomy of the antibody molecule. Mol Immunol 31: 169–217, 1994
Nguyen VK, Hamers R, Wyns L, Muyldermans S: Loss of splice consensus signal is responsiblefor the removal of the entire C(H)1 domain of the functional camel IGG2A heavy-chainantibodies. Mol Immunol 36: 515–524, 1999
Woolven BP, Frenken LG, van der Logt P, Nicholls PJ: The structure of the llama heavychain constant genes reveals a mechanism for heavy-chain antibody formation.Immunogenetics 50: 98–101, 1999
Decanniere K, Desmyter A, Lauwereys M, Arbabi-Ghahroudi M, Muyldermans S, Wyns L: Asingle-domain antibody fragment in complex with RNase A: non-canonical loop structures andnanomolar affinity using two CDR loops. Structure 7: 361–370, 1999
Renisio JG, Perez J, Czisch M, Guenneugues M, Bornet O, Frenken L, Cambillau C, Darbon H:Solution structure and backbone dynamics of an antigen-free heavy chain variable domain(VHH) from Llama. Proteins 47: 546–555, 2002
Spinelli S, Frenken L, Bourgeois D, de Ron L, Bos W, Verrips T, Anguille C, Cambillau C, Tegoni M: The crystal structure of a llama heavy chain variable domain. Nat Struct Biol 3:752–757, 1996
Decanniere K, Muyldermans S, Wyns L: Canonical antigen-binding loop structures inimmunoglobulins: More structures, more canonical classes? J Mol Biol 300: 83–91, 2000
Nguyen VK, Hamers R, Wyns L, Muyldermans S: Camel heavy-chain antibodies: diverse germline VHH and specific mechanisms enlarge the antigen-binding repertoire. EMBO J 19: 921–930, 2000
Harmsen MM, Ruuls RC, Nijman IJ, Niewold TA, Frenken LGJ, de Geus B: Llama heavy-chain Vregions consist of at least four distinct subfamilies revealing novel sequence features.Mol Immunol 37: 579–590, 2000
Desmyter A, Spinelli S, Payan F, Lauwereys M, Wyns L, Muyldermans S, Cambillau C: Threecamelid VHH domains in complex with porcine pancreatic alpha-amylase. Inhibition andversatility of binding topology. J Biol Chem 277: 23645–23650, 2002
Riechmann L, Muyldermans S: Single domain antibodies: Comparison of camel VH and camelisedhuman VH domains. J Immunol Methods 231: 25-38, 1999
Conrath K, Vincke C, Stijlemans B, Schymkowitz J, Decanniere K, Wyns L, Muyldermans S, Loris R: Antigen Binding and Solubility Effects upon the Veneering of a Camel VHH in Framework-2 to Mimic a VH. J Mol Biol 350: 112–125, 2005
Streltsov VA, Varghese JN, Carmichael JA, Irving RA, Hudson PJ, Nuttall SD: Structuralevidence for evolution of shark Ig new antigen receptor variable domain antibodies from acell-surface receptor. Proc Natl Acad Sci USA 101: 12444–12449, 2004
Thomassen YE, Meijer W, Sierkstra L, Verrips T: Large-scale production of VHHantibody fragments by Saccharomyces cerevisiae. Enzyme and Microbial Technology 30:273–278, 2002
Thomassen YE, Verkleij AJ, Boonstra J, Verrips CT: Specific production rate of VHHantibody fragments by Saccharomyces cerevisiae is correlated with growth rate, independentof nutrient limitation. J Biotechnol 2005
Hudson PJ, Kortt AA: High avidity scFv multimers; diabodies and triabodies. J Immunol Methods 231: 177–189, 1999
Turner DJ, Ritter MA, George AJ: Importance of the linker in expression of single-chain Fvantibody fragments: optimisation of peptide sequence using phage display technology. JImmunol Methods 205: 43–54, 1997
Perez JMJ, Renisio JG, Prompers JJ, van Platerink CJ, Cambillau C, Darbon H, Frenken LGJ:Thermal unfolding of a llama antibody fragment: A two-state reversible process.Biochemistry 40: 74–83, 2001
186.van der Linden RHJ, Frenken LGJ, de Geus B, Harmsen MM, Ruuls RC, Stok W, de Ron L, Wilson S, Davis P, Verrips CT: Comparison of physical chemical properties of llama V-HH antibodyfragments and mouse monoclonal antibodies. Biochim Biophys Acta 1431: 37–46, 1999
Zhang J, Tanha J, Hirama T, Khieu NH, To R, Tong-Sevinc H, Stone E, Brisson JR, MacKenzie CR: Pentamerization of Single-domain Antibodies from Phage Libraries: A Novel Strategy forthe Rapid Generation of High-avidity Antibody Reagents. J Mol Biol 335: 49–56, 2004
Lauwereys M, Arbabi-Ghahroudi M, Desmyter A, Kinne J, Holzer W, De Genst E, Wyns L, Muyldermans S: Potent enzyme inhibitors derived from dromedary heavy-chain antibodies.EMBO J 17: 3512–3520, 1998
Stijlemans B, Conrath K, Cortez-Retamozo V, Van Xong H, Wyns L, Senter P, Revets H, De Baetselier P, Muyldermans S, Magez S: Efficient targeting of conserved cryptic epitopes ofinfectious agents by single domain antibodies. African trypanosomes as paradigm. J Biol Chem 279: 1256–1261, 2004
Chapman AP: PEGylated antibodies and antibody fragments for improved therapy: A review.Adv Drug Deliv Rev 54: 531–545, 2002
Dennis MS, Zhang M, Meng YG, Kadkhodayan M, Kirchhofer D, Combs D, Damico LA: Albuminbinding as a general strategy for improving the pharmacokinetics of proteins. J Biol Chem277: 35035–35043, 2002
Conrath KE, Lauwereys M, Galleni M, Matagne A, Frere JM, Kinne J, Wyns L, Muyldermans S:Beta-lactamase inhibitors derived from single-domain antibody fragments elicited in thecamelidae. Antimicrob Agents Chemother 45: 2807–2812, 2001
Zhang J, Li Q, Nguyen TD, Tremblay TL, Stone E, To R, Kelly J, MacKenzie CR: A pentavalentsingle-domain antibody approach to tumor antigen discovery and the development of novelproteomics reagents. J Mol Biol 341: 161–169, 2004
Author information
Authors and Affiliations
Corresponding author
Additional information
Both authors contributed equally to this work.
Rights and permissions
About this article
Cite this article
Arbabi-Ghahroudi, M., Tanha, J. & MacKenzie, R. Prokaryotic expression of antibodies. Cancer Metastasis Rev 24, 501–519 (2005). https://doi.org/10.1007/s10555-005-6193-1
Issue Date:
DOI: https://doi.org/10.1007/s10555-005-6193-1